...Blincyto coverage expanded (Korea Biomedical Review) - Sep 1, 2026 - "National health insurance coverage is also being strengthened for treatments for serious blood cancers....Coverage for Blincyto in B-cell precursor ALL will also be expanded. Previously reimbursed for patients whose disease had relapsed or failed to respond to treatment, Blincyto will now be covered for earlier use after initial chemotherapy has eliminated detectable cancer cells, with the aim of eradicating residual disease. The ministry said the expansion could be particularly important for young children, as ALL has a high incidence among children under age 5."
Reimbursement • B Acute Lymphoblastic Leukemia
|